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Arsenic is ubiquitous in nature and is released
into the environment via industrial processes
and agricultural and medical applications
(Chan and Huff 1997). Because of the nat-
ural distribution, drinking water is the most
common source of arsenic exposure for the
general population (Gebel 2000), and mil-
lions of people worldwide suffer from arsenic
intoxication caused by drinking arsenic-cont-
aminated water (National Research Council
2001). Epidemiologic studies have shown a
strong association between chronic arsenic
exposure and various adverse health effects,
including cardiovascular diseases, neurologic
defects, and cancers of the lung, skin, blad-
der, liver, and kidney (Calderon et al. 2001;
Chen et al. 1985, 1995; Chiou et al. 2001;
Smith et al. 1992). Although the processes
involved in arsenic carcinogenesis remain an
enigma, a variety of mechanisms, both geno-
toxic and nongenotoxic, have been proposed
to explain the carcinogenicity of arsenic at the
cellular and molecular levels (Kitchin 2001;
Rossman 2003).
A risk of arsenic-induced chronic diseases,
such as cancer and cardiovascular diseases, is
clearly associated with prolonged exposure to
low doses of arsenic. Several studies have shown
that low doses of inorganic arsenic compounds
stimulate the proliferation of mammalian cells
(Barchowsky et al. 1999; Germolec et al. 1996;
Lee et al. 1985b). Furthermore, long-term
exposure to low concentrations of arsenic
causes increased neoplastic transformation of
murine JB6 Cl41 cells (Huang et al. 1999),
blast transformation of human lymphocytes
(Meng and Meng 2000), and malignant trans-
formation (tumors formed on injection of
arsenic-transformed cells into nude mice) of
the rat liver epithelial cell line TRL 1215
(Zhao et al. 1997), the human prostate epithe-
lial cell line RWPE-1 (Achanzar et al. 2002),
and the human osteosarcoma cell line TE85
(Mure et al. 2003). Long-term exposure to low
doses of arsenite also results in increased toler-
ance of acute arsenic exposure (Romach et al.
2000) and the aberrant expression of genes
involved in the regulation of a variety of cellu-
lar functions, including signal transduction,
the stress response, apoptosis, and cell prolifer-
ation (Chen et al. 2001a, 2001b; Vogt and
Rossman 2001). These studies strongly suggest
that chronic exposure to low levels of arsenic
can produce cellular changes that promote
arsenic-induced cell transformation or tumor
development.
Over the past few decades, numerous
genetic alterations affecting growth-controlling
genes have been identiﬁed in neoplastic cells,
providing persuasive evidence for the genetic
basis of human cancer (Lengauer et al. 1998).
All tumors contain genetic alterations, includ-
ing subtle changes in DNA sequences, gene
amplification, and gross chromosome losses,
gains, translocations, and aneuploidy (Cahill
et al. 1999; Schar 2001). Tumors exhibiting
abnormal karyotypes involving either chromo-
somal rearrangement and/or aneuploidy are
classified as chromosomal instability tumors
(Bardelli et al. 2001). Although arsenic-
induced malignant transformation has been
shown to be associated with DNA hypomethyl-
ation (Zhao et al. 1997), increased matrix met-
alloproteinase-9 secretion (Achanzar et al.
2002), and delayed mutagenesis (Mure et al.
2003), how arsenic induces genetic and epige-
netic alterations during cancer development
remains to be elucidated. Treatment with inor-
ganic trivalent arsenite results in the formation
of DNA single-strand breaks (Lynn et al.
1997) and in gene amplification (Lee et al.
1988; Yih and Lee 2000). Although inorganic
arsenic compounds are ineffective in inducing
point mutation in a variety of cultured cell
systems (Oberley et al. 1982; Rossman et al.
1980), they cause chromosomal damage in a
variety of in vitro (Hei et al. 1998; Jha et al.
1992; Lee et al. 1985a) and in vivo systems
(Gonsebatt et al. 1997). Inorganic arsenic is
generally accepted as a clastogenic agent.
We recently reported that treatment with
inorganic trivalent arsenite increases the fre-
quency of micronuclei (MN) and aneuploidy
in human ﬁbroblasts (Yih et al. 1997). These
arsenite-treated human fibroblasts were also
shown to have an unstable karyotype but
an increased life span (Yih et al. 1997). To
explore the association of chromosomal alter-
ations with arsenic-induced tumorigenicity in
epithelial cells, an immortalized but nontu-
morigenic human skin keratinocyte cell line,
HaCaT (Boukamp et al. 1988), was exposed
to low-dose inorganic trivalent arsenite for a
long period. Conversion of the cells from
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Inorganic arsenic is a well-documented human carcinogen. Chronic low-dose exposure to inorganic
arsenic is associated with an increased incidence of a variety of cancers, including skin, lung, blad-
der, and liver cancer. Because genetic alterations often occur during cancer development, the objec-
tive of this study was to explore what types of genetic alterations were induced by chronic exposure
of human HaCaT cells to arsenic. After 20 passages in the presence of inorganic trivalent arsenite at
concentrations of 0.5 or 1 µM, HaCaT cells had higher intracellular levels of glutathione, became
more resistance to arsenite, and showed an increased frequency of micronuclei. Furthermore, the
previously nontumorigenic HaCaT cells became tumorigenic, as shown by subcutaneous injection
into Balb/c nude mice. Cell lines derived from the tumors formed by injection of arsenite-exposed
HaCaT cells into nude mice expressed higher levels of keratin 6, a proliferation marker of ker-
atinocytes, than did parental HaCaT cells, whereas the expression of keratins 5, 8, and 10 was sig-
niﬁcantly decreased. Comparative genomic hybridization demonstrated chromosomal alterations in
the 11 cell lines derived from these tumors; all 11 showed signiﬁcant loss of chromosome 9q, and
seven showed signiﬁcant gain of chromosome 4q. The present results show that long-term exposure
to low doses of arsenite transformed nontumorigenic human keratinocytes to cells that were
tumorigenic in nude mice and that chromosomal alterations were observed in all cell lines estab-
lished from the tumors. Key words: arsenite, chromosomal alterations, comparative genomic
hybridization, HaCaT cells, tumorigenicity. Environ Health Perspect 112:1704–1710 (2004).
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strated by injection of arsenite-exposed cells
into nude mice. Chromosomal alterations in
the cell lines established from the resulting
tumors were analyzed using the comparative
genomic hybridization (CGH) technique,
which permits the rapid detection and map-
ping of DNA sequence copy number differ-
ences between a normal and an abnormal
genome (Kallioniemi et al. 1992). Our results
demonstrate that tumor cell lines derived from
tumors induced by injection with arsenite-
treated cells show chromosomal alterations.
Materials and Methods
Cell culture and treatment. HaCaT cells, kindly
provided by N.E. Fusenig (German Cancer
Research Center, Heidelberg, Germany), were
routinely grown in Dulbecco’s modiﬁed Eagle
medium (GIBCO, Grand Island, NY, USA)
supplemented with 10% fetal bovine serum
(GIBCO), 1% glutamine, and antibiotics
(100 U/mL penicillin and 100 µg/mL strep-
tomycin) (Boukamp et al. 1988). For long-
term exposure of HaCaT cells to arsenite, 5 ×
105 cells were plated onto a 100-mm Petri
dish and were fed with medium containing
various concentrations of sodium arsenite (0,
0.5, and 1 µM). Every 4 days, the cells, grown
to near conﬂuence, were subcultured, replated
at the same cell density, and fed with arsenite
at the same concentration. Subculturing was
continued for 20 passages, and the accumulated
population doublings during these 20 passages
were calculated. HaCaT cells that had been
exposed to 0, 0.5, or 1 µM sodium arsenite for
20 passages were designated as A0, A1, or A2
cells, respectively.
Cytotoxicity assay. We determined the
cytotoxicity of arsenite using the colony-
forming assay or the sulforhodamine B (SRB)
assay. The colony-forming assay was per-
formed as described previously (Ho and Lee
1999). In brief, the HaCaT cells were treated
with various concentrations of sodium arsenite
for 24 hr and replated at 200 cells per 60-mm
dish in triplicate. Then, after incubation for
10 days, the colonies were ﬁxed, stained, and
counted under a dissection microscope. The
SRB assay (Skehan et al. 1990) was performed
using 96-well microplates and a density of
1,000 HaCaT cells/well. After addition of
sodium arsenite, the microplates were incu-
bated for 72 hr, and then the cells were ﬁxed
for 1 hr with ice-cold 50% trichloroacetic acid
and stained for 30 min with 0.4% (wt/vol)
SRB in 1% acetic acid solution. After extensive
washes with distilled water, the bound SRB
was extracted with 100 µL 10-mM unbuffered
Tris-base solution and measured using a
96-well plate reader (Bio-Rad model 550; Bio-
Rad, Hercules, CA). The survival curves were
plotted by expressing the absorbance of treated
wells as a percentage of that of control wells,
and the inhibitory concentration 50% (IC50)
values were calculated by linear regression.
Glutathione determination. Cellular gluta-
thione (GSH) levels in logarithmically grow-
ing cells were determined as described by
Cohn and Lyle (1966).
Cytokinesis-block MN assay. We used the
method of Fenech and Morley (1989) with
slight modiﬁcations to analyze the frequency
of arsenite-induced MN. In brief, A0, A1,
and A2 cells were incubated for 30 hr with
2 µg/mL cytochalasin B and then treated for
150 sec with hypotonic solution (0.05%
KCl). After fixation for 8 min in a 20:1
(vol/vol) mixture of methanol and acetic acid,
the cells were stained for 10 min with 5%
(vol/vol) Giemsa solution, and then the num-
ber of MN was scored in 1,000 binucleate
cells; under the conditions used, the fre-
quency of binucleate cells was 500–600 per
1,000 cells.
Tumorigenicity test and establishment of
tumor cell lines. Male Balb/c nude mice 4–6
weeks of age, obtained from the National
Laboratory Animal Center (Taipei, Taiwan),
were injected subcutaneously with 3 × 106 A0,
A1, or A2 cells in 100 µL of phosphate-
buffered saline (PBS), pH 7.4, at each of two
sites on either side of the back. Five animals
were used per cell line and were maintained
on regular food and water. To monitor tumor
formation, we measured the longest and short-
est diameters of the tumors weekly, starting
when the tumor was ﬁrst apparent. At the end
of the experiment, the tumors were excised,
and then part of the tumor tissue was ﬁxed in
buffered formalin for histologic examination,
and another part was washed with PBS,
minced, digested with collagenase type IV,
and seeded in a Petri dish to establish tumor
cell lines. Three cell lines, designated T1, T2,
and T3, were established from the A1-derived
tumors, and two lines, T4 and T5, from
A2-derived tumors. To conﬁrm their tumori-
genicity, we injected 3 × 106 T1 and T4 cells
in 100 µL of PBS into Balb/c nude mice and
monitored tumor formation as described
above. Two further cell lines, designated
T1R1 and T1R2, and four other cell lines,
designated T4R1–T4R4, were established
from the T1- and T4-induced tumors, respec-
tively. In a separate experiment to see if arsenic
enhanced tumor progression, five other cell
lines, T4A1–T4A5, were derived from tumors
in T4-injected Balb/c nude mice that were also
given arsenite-containing water (30–50 ppb)
from 1 week before injection until the end of
the experiment.
Western blotting analysis of keratins.
Logarithmically growing cells were scraped
from culture dishes using a rubber policeman,
lysed immediately in electrophoretic sample
buffer, and heated at 95°C for 10 min
(Laemmli 1970). Protein concentrations were
determined by the Bio-Rad protein assay (Bio-
Rad). An aliquot containing 10–20 µg protein
was loaded onto a 10% sodium dodecyl 
sulfate–polyacrylamide gel, and then, after
electrophoretic separation, the proteins were
transferred onto a polyvinylidene difluoride
membrane using a semidry electrotransfer sys-
tem (ATTO, Tokyo, Japan). After blocking
with 5% milk in PBS containing 0.2% Tween
20 for 1 hr at room temperature, the mem-
branes were reacted with primary antibodies
against keratin 5/8, 6, 7/17, 10, 14, or 18
(Santa Cruz Biotechnology, Santa Cruz, CA,
USA) and horseradish peroxidase–conjugated
secondary antibody (Organon Teknika-
Cappel, Turnhout, Belgium) as previously
described (Yih and Lee 2000). Keratins were
then visualized using an enhanced chemi-
luminescence system according to the manu-
facturer’s instructions (Pierce, Rockford, IL,
USA).
Chromosomal alteration analysis by CGH.
CGH was performed essentially as described
by Kallioniemi et al. (1992) on normal male
human lymphocyte metaphase spreads. DNA
isolated from control HaCaT cells or cells
derived from arsenite-induced tumors was
labeled via nick translation with Spectrum
red–2´-deoxyuridine 5´-triphosphate (dUTP)
and ﬂuorescein isothiocyanate-dUTP, respec-
tively (Vysis, Downers Grove, IL, USA) and
the 500–3,000 bp products were used as the
probe for CGH. After hybridizing the probe
with the spreads for 48–72 hr at 37°C, the
slides were washed and counterstained with
4´,6´-diamidino-2´-phenylindole, and then
metaphases were examined under a Zeiss
Axioskop microscope equipped with appropri-
ate epiﬂuorescence ﬁlters and a charge-coupled
device camera (SenSys; Photometrics, Tucson,
AZ, USA) controlled by the SmartCapture
program (Vysis). The filter system (Chroma
Technology, Brattleboro, VT, USA) consisted
of a triple-bandpass beam splitter and a triple-
bandpass computer-controlled filter wheel
(Ludl Electronic Products, Hawthorne, NY,
USA). Image acquisition, profile generation,
and analysis were performed using the Quips
XL genetics workstation system (Vysis). After
karyotyping, we calculated the green-to-red
ratio proﬁles down the axis of each chromo-
some. Data from 10 captured metaphases
were used to generate a mean proﬁle ± 1 SD
per hybridization. Threshold values of 1.2
and 0.8 were set to identify the presence of
gains and losses, respectively. To avoid bias
due to possible different afﬁnities of the ﬂuo-
rochromes for the DNA, we repeated the
hybridization experiment using the same
DNA samples from HaCaT cells and arsen-
ite-induced tumor cells, but with the fluo-
rochromes reversed, and used the results from
the two hybridizations to determine the gains
and losses.
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Increased intracellular GSH levels and arsenite
resistance in long-term arsenite-exposed cells.
When the colony-forming assay was performed
on HaCaT cells treated with arsenite for 24 hr,
the value of IC50 was 8.7 µM. In a pilot study,
0.5 or 1 µM arsenite did not affect HaCaT cell
proliferation. We therefore exposed HaCaT
cells continuously for 20 passages to 0, 0.5, or
1 µM arsenite and designated the final cell
populations as A0, A1, and A2 cells, respec-
tively. At the doses used, arsenite did not sig-
nificantly affect the growth rate of HaCaT
cells; the accumulated population doublings
ranged from 58 to 67 (Figure 1A). However,
when the A0, A1, and A2 cells were then
exposed to higher concentrations of sodium
arsenite (0–16 µM) for 72 hr, the IC50 values
for arsenite, examined using the SRB assay,
were 2.2 ± 0.3, 3.2 ± 0.4, and 3.7 ± 0.5 µM,
respectively (Figure 1B). The IC50 values for
the A1 and A2 cells were signiﬁcantly higher
than that for A0 cells, showing that the A1
and A2 cells were more resistant to arsenite.
Consistent with previous reports showing that
elevated GSH levels are frequently associated
with arsenic resistance (Brambila et al. 2002;
Lee et al. 1989), intracellular GSH levels in A1
and A2 cells were significantly higher than
those in A0 cells (Figure 1C).
Increased MN formation in long-term
arsenite-exposed cells. MN, which generally
result from the loss of whole chromosomes or
chromosome fragments, are frequently used to
monitor chromosomal damage and/or insta-
bility in in vitro and in vivo systems (Fenech
2000). We examined the frequency of MN in
A0, A1, and A2 cells immediately after expo-
sure to arsenite for 20 passages by using the
cytokinesis-block MN technique. As shown in
Figure 1D, the frequency of MN in A1 and
A2 cells was signiﬁcantly higher than that in
A0 cells, indicating that long-term exposure to
low doses of arsenite resulted in increased
chromosomal damage.
Tumorigenicity of HaCaT cells after long-
term exposure to a low dose of arsenite. We
examined the tumorigenicity of A0, A1, and
A2 cells by injecting the cells into Balb/c
nude mice. As shown in Figure 2, no tumor
growth was seen after injection of A0 cells,
whereas tumors were seen 2 months after
injection of A1 or A2 cells. As summarized in
Table 1, tumors were formed at ﬁve or seven
of the 10 sites injected with A1 or A2 cells,
respectively. Histologic examination of the
tumors revealed the formation of a multilay-
ered, hyperproliferative, keratinizing epithe-
lium (Figure 3A,B). When two tumor cell
lines, T1 and T4—derived, respectively, from
tumors induced by injection with A1 or A2
cells—were reinjected into nude mice to
confirm their tumorigenicity, tumors were
rapidly formed within 2 weeks at almost all
Article | Chien et al.
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Figure 1. Effects of long-term sodium arsenite treatment on accumulated population doubling, arsenic
resistance, intracellular GSH levels, and MN frequency. (A) HaCaT cells continuously treated for 20 pas-
sages with 0, 0.5, or 1 µM sodium arsenite and then designated as A0, A1, and A2 cells. (B) A0, A1, and A2
cells treated with different concentrations of sodium arsenite for 72 hr, and cell survival determined using
the SRB assay and the IC50 values calculated by linear regression. (C) Intracellular GSH levels in A0, A1,
and A2 cells. (D) MN analysis performed on A0, A1, and A2 cells. In (B–D), the data are the means ± SD for
three independent experiments.
*p < 0.05 by Student’s t-test (C) and by Fisher’s exact test (D).
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Figure 2. Growth curves of tumors formed in nude mice by subcutaneous injection of A0, A1, A2, or T4
cells. Tumor size (longest × shortest2 diameter × 0.5 in mm3), measured once a week starting 1 month
(A0–A2 cells) or 2 weeks (T4 cells) after injection, is plotted against time. (A) A0 cells. (B) A1 cells. (C) A2
cells. (D) T4 cells. The horizontal lines indicate 30 mm3, and a tumor size greater than this was considered
tumor formation in Table 1.injection sites (Figure 2D, Table 1). Their
histologic phenotypes were clearly more
malignant than those formed after injection
with A1 or A2 cells (Figure 3C,D). When T4
cells were injected into nude mice given
arsenite-containing water from 1 week before
injection until the end of the experiment, the
number of tumors formed and the rate of
tumor formation were the same as in similarly
injected nude mice given arsenite-free water
(data not shown), showing that the continued
presence of arsenite did not enhance tumor
progression.
Altered keratin expression in long-term
arsenite-exposed cells and cell lines derived
from arsenite-induced tumors. Keratins are
components of intermediate ﬁlaments and play
an essential role in cytoskeleton formation
(Morley and Lane 1994). They are involved in
a variety of cell functions, and alterations in
keratin expression are closely associated with
tumor progression (Chu and Weiss 2002).
With Western blotting, the levels of keratins 5,
6, 7, 8, 10, and 17 were signiﬁcantly decreased
in A1 and A2 cells compared with A0 cells
(Figure 4A), whereas levels of keratins 14 and
18 remained relatively constant. A signiﬁcant
decrease in levels of keratins 5, 8, and 10 was
also observed in all cell lines established from
tumors (Figure 4B). The expression of these
keratins in T1R2 and T4R2 cells was in gen-
eral lower than that in the parental T1 and T4
cells. The levels of keratins 7, 14, 17, and 18
did not change in these cell lines, whereas,
because of the very low levels in A0 cells, the
levels of keratin 6, a proliferation marker, were
markedly increased (Figure 4B).
Identiﬁcation of chromosomal alterations
in cell lines derived from long-term arsenite-
exposed cells. To evaluate the presence of
genetic changes in arsenite-induced tumors, we
performed CGH analysis to analyze DNA
sequence copy number changes in cell lines
derived from tumors produced by injection
with A1 or A2 cells or cell lines derived from
the resulting tumors. The major changes found
in these cell lines were gain of chromosome
4q and loss of chromosome 9q (Figure 5A).
Other regions occasionally showing gain and
loss of chromosome regions are summarized in
Figure 5A. In a detailed comparison (Figure
5B), all ﬁve tumor cell lines established from
A1 and A2 cells (lines T1–T5) showed gain of
chromosome 4q and loss of a large region of
chromosome 9q. However, although all six of
the cell lines derived from tumors formed by
injection with T4 cells showed loss of chromo-
some 9q, only two (lines T4R4 and T4A1)
showed gain of chromosome 4q. These results
show that 9q12–22 was lost in all these cell
lines and that chromosomal alteration, particu-
larly loss of chromosome 9q, was a common
event in tumor cells derived from arsenite-
exposed HaCaT cells.
Discussion
Chronic arsenic exposure results in skin pathol-
ogy, including hyperkeratosis, pigmentation
changes, Bowen’s disease, basal cell carcinomas,
and squamous cell carcinomas (Centeno et al.
2002). In the present study, we demonstrated
that long-term low-dose exposure to sodium
arsenite converted the nontumorigenic human
keratinocyte HaCaT cell line into cells that
were tumorigenic in nude mice. Histology of
the tumors caused by injection of arsenite-
treated HaCaT cells showed epithelial hyper-
plasia, mild dysplasia, severe dysplasia, and
invasive carcinoma. These phenotypes are simi-
lar to arsenic-induced skin pathology. These
results showing the induction of neoplastic
transformation by long-term exposure of non-
tumorigenic cells to low doses of arsenite are
consistent with those of several other studies
using different cell systems (Achanzar et al.
2002; Huang et al. 1999; Mure et al. 2003;
Zhao et al. 1997).
Consistent with several previous reports
(Brambila et al. 2002; Lee et al. 1989; Romach
et al. 2000), we showed that long-term expo-
sure of HaCaT cells to low doses of arsenite
resulted in an increase in intracellular GSH
levels and resistance to arsenite challenge.
These results also suggested that the insults
produced by low-dose arsenite stress modu-
lated the cellular biochemistry to adapt to the
growth environment. Because acquisition of
a survival advantage is crucial for the develop-
ment of cancer (Hanahan and Weinberg 2000),
long-term exposure to arsenite, even at low
doses, warrants concern.
In in vitro systems, arsenite induces MN in
a variety of cells (Eastmond and Tucker 1989;
Liu and Huang 1997; Wang and Huang
1994). Both low-dose and high-dose exposure
to arsenite induces MN formation (Yih and
Lee 1999), but low-dose treatment results
mainly in kinetochore-positive (K+) MN,
whereas high-dose treatment results mainly in
K-negative MN. K+ MN are usually caused by
failure of the whole chromosome to segregate
into daughter cells, and agents inducing aneu-
ploidy by interfering with spindle formation
often induce K+ MN formation (Eastmond
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Table 1. Tumorigenicity of arsenite-exposed cells and cell lines derived from arsenite-induced tumors
after subcutaneous injection into nude mice.
Cellsa Days No. of tumors/no. of injections (%) Tumor size (mm3)b
A0 128 0/10 (0)
A1 5/10 (50) 68.3 (36.5–174.1)
A2 7/10 (70) 119.0 (42.1–314.1)
T1 35 4/4 (100) 146.5 (105.4–185.6)
T4 94 8/10 (80) 413.2 (78.9–1242.8)
aA0, A1, and A2, ﬁnal cell lines after treatment with 0, 0.5, or 1 µM sodium arsenite, respectively, for 20 passages; T1 and
T4, cell lines derived from tumors induced by injection with A1 cells or A2 cells, respectively. bTumor size = longest ×
shortest2 diameter (in mm) × 0.5.
A B
C D
Figure 3. Histologic examination of tumors formed in nude mice. Tumors showing a hyperplastic stratiﬁed
epithelium with prominent parakeratosis formed by injection of A1 cells (A) or A2 cells (B). Tumors with more
malignant characteristics formed by injection of cell lines T1 (C) or T4 (D). Bars = 50 µm.and Tucker 1989). Thus, low-dose arsenite
may be considered an aneugen. In fact, an
increased frequency of MN has been demon-
strated in exfoliated bladder cells, buccal cells,
sputum cells, and lymphocytes from arsenic-
exposed populations (Rossman 2003). The
increased frequency of MN seen in A1 and A2
cells in this study shows that long-term expo-
sure to low-dose arsenite can cause chromoso-
mal damage. Because chromosomal alterations
are a general manifestation of tumors (Cahill
etal. 1999; Schar 2001), the effects of arsenic-
induced chromosomal damage may play a role
in arsenic tumorigenesis.
Keratins are the major structural proteins
in epithelial cells and consist of a family of pro-
teins (Morley and Lane 1994). Several human
genetic diseases provide evidence that keratins
function to protect cells from mechanical and
nonmechanical stresses that result in cell death
(Fuchs and Cleveland 1998; Ma et al. 2001).
The expression of keratins is affected by cellu-
lar differentiation, environmental stimuli, and
diseases (Morley and Lane 1994). Progressive
alterations in keratin expression are closely
associated with the development of a variety of
tumors (Chu and Weiss 2002). In our present
study, long-term exposure of HaCaT cells to
low-dose arsenite caused a reduction in the
levels of keratins 5, 6, 7, 8, 10, and 17, and the
cell lines derived from tumors induced by
injection with arsenite-treated cells had a simi-
lar pattern of expression of keratins, except that
the levels of keratins 7 and 17 were unchanged
and keratin 6 levels were signiﬁcantly increased
in the tumor cell lines. These results show that
long-term arsenite exposure can alter regula-
tion of keratin expression. Levels of keratin 6,
a marker of hyperproliferative keratinocytes
(Tomic-Canic et al. 1998), are increased dur-
ing wound healing, psoriasis, and other inﬂam-
matory disorders (Tomic-Canic et al. 1998).
Furthermore, increased levels of keratins 6 and
16 have been reported in arsenic-induced
Bowen’s disease, and increased levels of ker-
atins 6, 16, and 17 are seen in arsenic-induced
squamous cell carcinoma and basal cell carci-
noma (Yu et al. 1993). The increased keratin 6
expression seen in tumor cell lines derived
from long-term arsenite-exposed HaCaT cells
suggests that keratin 6 is a good proliferation
marker for arsenite-induced carcinogenesis.
Using CGH analysis, we demonstrated
genetic changes in cells exposed to low-dose
arsenite for a long time. Because gain of chro-
mosome 4q and loss of 9q were observed in
most of the cell lines established, these non-
random changes are possibly important genetic
events in arsenic tumorigenesis. However,
although gain of chromosome 4q was seen
in all five lines cells derived from A1- and
A2-induced primary tumors (lines T1–T5), it
was only seen in two (T4R4 and T4A1) of six
cell lines derived from T4-induced secondary
tumors. This suggests that gain of chromosome
4q might not be crucial for arsenite-induced
tumorigenicity. On the other hand, loss of
chromosome 9q was consistently observed in
all primary and secondary tumor cell lines
established in this study, suggesting that it
plays an essential role in arsenite-induced
tumorigenicity. Deletion of all or part of
chromosome 9q is seen in tumors from
patients exposed to arsenic (Moore et al. 2002).
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B A
A0 A1 A2 A0 T1 T4 T1R2 T4R2
1.0 0.5 ± 0.2* 0.5 ± 0.2* 1.0 0.8 ± 0.1* 0.7 ± 0.0* 0.3 ± 0.3* 0.2 ± 0.3*
1.0 0.6 ± 0.2* 0.3 ± 0.3* 1.0 32.5 ± 17.7* 17.5 ± 2.8* 14.3 ± 7.9* 29.0 ± 8.1*
1.0 0.6 ± 0.2* 0.4 ± 0.2* 1.0 1.2 ± 0.4 1.2 ± 0.4 0.8 ± 0.4 1.0 ± 0.6
1.0 0.8 ± 0.1* 0.6 ± 0.2* 1.0 0.8 ± 0.1* 0.9 ± 0.1* 0.6 ± 0.1* 0.7 ± 0.1*
1.0 0.6 ± 0.2* 0.4 ± 0.3* 1.0 0.8 ± 0.0* 0.8 ± 0.1* 0.6 ± 0.2* 0.0 ± 0.0*
1.0 0.8 ± 0.1 0.8 ± 0.3 1.0 1.1 ± 0.1 1.2 ± 0.1* 0.9 ± 0.1 1.2 ± 0.3
1.0 0.6 ± 0.2* 0.4 ± 0.2* 1.0 1.2 ± 0.4 1.2 ± 0.4 0.8 ± 0.4 1.0 ± 0.6
1.0 1.0 ± 0.2 1.0 ± 0.2 1.0 1.0 ± 0.1 1.0 ± 0.1 0.9 ± 0.2 1.0 ± 0.3
K5
K6
K7
K8
K10
K14
K17
K18
Figure 4. Western blotting analysis of keratins in arsenite-exposed cells and cell lines derived from tumors
induced by injection of arsenite-treated cells. (A) Keratin levels in A0, A1, and A2 cells. (B) Keratin levels in
cell lines derived either from tumors induced by injection of arsenite-treated cells (T1 and T4) or from
those induced by injection of lines T1 or T4 (T1R2 and T4R2). β-Actin was used as the loading control and
to normalize the keratin expression levels. The normalized expression level in each cell type was then
compared with that in A0 cells. The data are the means ± SD for three independent experiments.
*p < 0.05 by Student’s t-test.
B A
12 3 4 56 78 9 1 0
11 12 13 14 15 16 17 18 19 20 21 22 4 1 2 3 4 5 910 1 2 3 45 910 678 1 19
1–5: T1–T5
6–9: T4R1–T4R4
  10: T4A1
  11: T4A3
Figure 5. CGH analysis of cell lines derived from arsenite-induced tumors. (A) All cell lines were compared
with HaCaT cells. Chromosomal loss is indicated by a line to the left of each chromosome, and a gain by a
line to the right. The entire X and Y chromosomes were excluded from analysis. (B) Chromosomal gain at
the 4q region and loss at the 9q region in individual cell lines. Lines T1–T5 were derived from tumors
induced in mice injected with A1 or A2 cells, whereas the other six lines were from tumors induced by
injection of T4 cells.As reported by Boukamp et al. (1997), HaCaT
cells are spontaneously immortalized human
skin keratinocytes and remain nontumorigenic
up to 300 passages (Boukamp et al. 1997).
Because translocations and deletions occurred
during late passages, the presence of rare
tumorigenic variants in A0 cells warrants our
concern. However, it is unlikely because the sus-
tained nontumorigenic phenotype of HaCaT
cells during long-term propagation is well associ-
ated with their preserved chromosomal balance
demonstrated by karyotypic and CGH analysis
(Boukamp et al. 1997).
The association of chromosomal alter-
ations with cancer development is a compli-
cated issue. Gain of chromosome 4q or loss
of 9q has been found in a variety of cancers,
including skin, bladder, and lung cancers
(Hartmann et al. 2002; Merlo et al. 1994;
Popp et al. 2000), but other studies found an
association between loss of chromosome 4q or
gain of 9q and cancer development (Balsara
et al. 2001; Jin et al. 2001). These studies
indicate the presence of both tumor suppres-
sor genes and oncogenes on these chromo-
somal regions. The genes for chemokine
ligands 1, 2, and 3 are localized on chromo-
some 4q (Haskill et al. 1990) and are con-
sidered oncogenes because of their growth
stimulatory activity. Two putative tumor sup-
pressor genes, deleted in bladder cancer 1
(DBC1) and deleted in esophageal cancer 1
(DEC1), are localized on chromosomal 9q.
Loss of heterozygosity of DBC1 is seen in
some bladder cancers (Habuchi et al. 1998),
whereas DEC1 expression is reduced or absent
in esophageal squamous cell carcinomas
(Nishiwaki et al. 2000). The expression of
these genes and its relationship to arsenic car-
cinogenesis require further investigation.
In conclusion, our results demonstrate
that long-term exposure to low doses of arsen-
ite can cause genetic instability and lead to
conversion of nontumorigenic human epithe-
lial cells into cells that are tumorigenic in nude
mice. However, the oncogenes and/or tumor
suppressor genes involved in arsenic-induced
carcinogenesis require further investigation.
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